Smithers announces Peron as president of Medical Device Testing Division
25 Aug 2023
Executive Change
Smithers, a provider of testing, consulting, information, and compliance services, announces the appointment of Gael Peron as president of Smithers Medical Device Testing Division.
As the President, Peron will provide direction and leadership to Smithers medical device and pharmaceutical testing laboratories in Akron, Ohio, USA and Shawbury, United Kingdom. These laboratories provide chemical analysis and physical and functional testing services for medical products including injectable devices like combination products, as well as single use technologies (SUTS) and parenterals.
The chemical analysis laboratory performs extractables and leachables testing programs designed to fulfil the global regulatory requirements for container systems and materials. The physical and functional laboratory offers standard and non-standard medical device testing on a range of drug delivery devices, accessories, and packaging to ensure products are compliant and fit for use.
“Under Gael’s leadership, the Medical Device Testing Division has seen consistent, sustainable growth globally,” states Michael Hochschwender, CEO, Smithers. “In his new role as president, we are confident that Gael will continue to demonstrate Smithers commitment accurate data, on time, with high touch as the Medical Device Testing Division grows and expands into new markets.”
Peron joined Smithers in 2020 as the vice president of the Medical Device Testing Division. He has over eighteen years of experience bringing medical products and devices to market. He holds a Master’s of Science in biotechnology from the graduate school ENSTBB Bordeaux and worked previously at Sartorius Stedim Biotech and Charter Medical.
Smithers Medical Device Testing Division helps medical device and pharmaceutical product manufacturers bring innovative, compliant and products to market with the company's expertise and independent medical device testing capabilities.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.